Notable Two Hundred Day Moving Average Cross - COR
In trading on Thursday, shares of Cencora Inc (Symbol: COR) crossed below their 200 day moving average of $323.14, changing hands as low as $321.12 per share. Cencora Inc shares are currently trading off about 1.8% on the day. The chart below shows the one year performance of...
Nasdaq News: Markets
More News
McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate
McKesson raises fiscal 2027 EPS guidance as oncology, GLP-1 volumes and specialty distribution drive faster profit growth despite cash-flow pressure.
Zacks
Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?
McKesson's double-digit earnings growth, specialty expansion and capital returns support the story, but a premium valuation leaves less room for error.
Zacks
$100 Invested In Cencora 10 Years Ago Would Be Worth This Much Today
Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.61% on an annualized basis producing an average annual return of 19.99%. Currently, Cencora has a market capitalization of $60.51 billion.read more...
Why Cencora (COR) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Here's Why Cencora (COR) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Will Pharma and Specialty Demand Boost Cardinal Health's Q4 Results?
Cardinal Health heads into Q4 earnings with pharma, specialty and higher-margin businesses in focus as investors watch if growth offsets pricing headwinds.
Zacks
COR Stock Gains as Q3 Earnings Beat on Segment Growth, EPS View Raised
Cencora's fiscal Q3 EPS beats estimates as broad segment growth lifts profit, prompting a higher 2026 outlook despite a slight revenue miss.